Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hangzhou Diagens Biotechnology Co PB Ratio?
Hangzhou Diagens Biotechnology CoHKSE:02526 -1.07%8 PB Ratio is 36.68 as of Aug. 14, 2026, which is 74% below its 10-year median of 139.32. GuruFocus rates HKSE:02526 with a GF Score™ of 8/100. The stock has 2 warning signs investors should review. Among 783 Medical Devices & Instruments companies, Hangzhou Diagens Biotechnology Co ranks worse than 97.7% on this metric.
HKSE:02526'
s PB Ratio Range Over the Past 10 Years
Min: 26.67 Med: 139.32 Max: 172.33
Current: 36.67
During the past 3 years, Hangzhou Diagens Biotechnology Co's highest PB Ratio was 172.33. The lowest was 26.67. And the median was 139.32.
HKSE:02526's PB Ratio is ranked worse than 97.7% of 783
companies
in the Medical Devices & Instruments industry
Industry Median: 2.13
vs HKSE:02526: 36.67
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Hangzhou Diagens Biotechnology Co PB Ratio Related Terms
Hangzhou Diagens Biotechnology Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Diagens Biotechnology Co PB Ratio Chart
Hangzhou Diagens Biotechnology Co Annual Data
Trend
Dec23
Dec24
Dec25
PB Ratio
0.00
0.00
0.00
Hangzhou Diagens Biotechnology Co Quarterly Data
Dec23
Dec24
Sep25
Dec25
Jun26
PB Ratio
0.00
0.00
0.00
0.00
30.71
HKSE:02526 vs ABT, SYK, MDT: PB Ratio Comparison
For the Medical Devices subindustry, Hangzhou Diagens Biotechnology Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Diagens Biotechnology Co PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Hangzhou Diagens Biotechnology Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Hangzhou Diagens Biotechnology Co's PB Ratio falls into.
Hangzhou Diagens Biotechnology Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a PB Ratio of 36.68 as of Aug. 14, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hangzhou Diagens Biotechnology Co and its competitors. This is 74% below median its historical median of 139.32. Over the past decade, Hangzhou Diagens Biotechnology Co's PB Ratio has ranged from 26.67 to 172.33. According to the industry distribution chart, Hangzhou Diagens Biotechnology Co ranks #765 out of 783 companies in the Medical Devices & Instruments industry, placing it in the top 97.7%.
Is Hangzhou Diagens Biotechnology Co's PB Ratio too high?
Hangzhou Diagens Biotechnology Co's current PB Ratio of 36.68 is 74% below median its 10-year median of 139.32. Over the past 10 years, this metric has ranged from a low of 26.67 to a high of 172.33. The Medical Devices & Instruments industry median PB Ratio is 2.13. Hangzhou Diagens Biotechnology Co's value of 36.68 is 1622.1% above this industry median. Based on the distribution chart, Hangzhou Diagens Biotechnology Co ranks #765 out of 783 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Hangzhou Diagens Biotechnology Co has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Diagens Biotechnology Co's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Hangzhou Diagens Biotechnology Co ranks #765 out of 783 companies for PB Ratio. This places Hangzhou Diagens Biotechnology Co in the lower half of its industry. The industry median PB Ratio is 2.13. Hangzhou Diagens Biotechnology Co's value of 36.68 is 1622.1% above this benchmark. Historically, Hangzhou Diagens Biotechnology Co's own PB Ratio has ranged from 26.67 to 172.33 over the past decade. While the company's 10-year median is 139.32 vs. the industry median of 2.13, Hangzhou Diagens Biotechnology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.13, based on 783 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Diagens Biotechnology Co's current PB Ratio of 36.68 is 1622.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Hangzhou Diagens Biotechnology Co and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Diagens Biotechnology Co's current PB Ratio is 36.68, which is 74% below median its own 10-year median of 139.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Diagens Biotechnology Co stock overvalued right now?
Hangzhou Diagens Biotechnology Co (HKSE:02526) has a current PB Ratio of 36.68. The current PB Ratio is 36.68, which is 74% below median its 10-year median of 139.32 and 1622.1% above the Medical Devices & Instruments industry median of 2.13. Hangzhou Diagens Biotechnology Co's overall GF Score™ is 8/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Hangzhou Diagens Biotechnology Co (HKSE:02526), the current PB Ratio is 36.68 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hangzhou Diagens Biotechnology Co Ltd and its subsidiaries are involved in the development and commercialisation of medical imaging artificial intelligence technologies and medical imaging equipment. It has self-developed a diversified portfolio, including six medical imaging software products, three commercialized medical devices, four key reagents and consumables and two technology licensing offerings. Its Core Product, AI AutoVision, is an auxiliary diagnostic software designed to undertake intelligent analysis on chromosome karyotyping. The majority of the company's revenue is derived from Technology Licensing, mainly in the Chinese mainland.
8GF Score
Get the complete analysis for HKSE:02526
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02526 has been successfully added to your 
